Get to know our clinical trials

Phase Ib/II, unblinded, randomized, platform clinical trial to evaluate the safety and efficacy of therapeutic combinations of AB928 in patients with metastatic colorectal cancer.

THE GOAL OF THIS STUDY IS TO HELP THE DEVELOPER LEARN WHETHER THE INVESTIGATIONAL DRUG, CALLED ETRUMA (AB928), WHICH HAS NOT YET BEEN APPROVED FOR USE, IS SAFE AND EFFECTIVE AS PART OF A POLYTHERAPY FOR THE POTENTIAL TREATMENT OF MRCC.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE IB/II, UNBLINDED, RANDOMIZED, PLATFORM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THERAPEUTIC COMBINATIONS OF AB928 IN PATIENTS WITH METASTATIC COLORECTAL CANCER.
  • Code EudraCT: 2020-005386-13
  • Protocol number: ARC-9
  • Promoter: Arcus Biosciencies
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.